EC Number   |
Application |
Reference |
|---|
    1.14.11.1 | drug development |
enzyme BBOX is a drug target for the treatment of myocardial infarction |
745684 |
| 1.14.11.1 | medicine |
activity of gamma-butyrobetaine dioxygenase in the liver is lower in pigs treated with clofibrate than in control pigs. Concentrations of gamma-butyrobetaine does not differ between both groups. Pigs treated with clofibrate have higher relative mRNA concentrations of organic cation transporter OCTN2 in liver, skeletal muscle and epithelial cells from small intestine than control pigs. Pigs treated with clofibrate have also higher concentrations of free and total carnitine in the liver and a higher concentration of free carnitine in skeletal muscle than control pigs |
686566 |
| 1.14.11.1 | medicine |
BBOX is a therapeutic target in humans, the BBOX inhibitor mildronate is used to decrease fatty acid oxidation in patients after myocardial infarction |
745953 |
| 1.14.11.1 | medicine |
both enhancement of carnitine biosynthesis due to increased ?-butyrobetaine dioxygenase activity, extra-hepatic gamma-butyrobetaine synthesis and increased hepatic carnitine import contributes to the increased hepatic carnitine levels after fasting |
685321 |
| 1.14.11.1 | medicine |
effects of hyperthyroidism and hypothyroidism on enzyme activity |
439302 |
| 1.14.11.1 | medicine |
inhibition of BBOX is reported to aid in recovery after acute stroke |
744503 |
| 1.14.11.1 | molecular biology |
a fluorescence assay based on the detection of fluoride released from reactions of fluorinated substrates with BBOX by the use of tert-butyldimethylsilyl-protected fluorescein is developed. (3S)-3-fluoro-4-(trimethylammonio)butanoate is a good substrate for BBOX, releasing fluoride when subjected to the enzyme |
727308 |
